Optical

STAAR Surgical Celebrates Three Million Lens Milestone at ASCRS Meeting, Unveils New EVO ICL Data and Latest Innovation for 2024

Retrieved on: 
Tuesday, April 2, 2024
Biotechnology, Practice Management, Optical, Surgery, General Health, Health, Hospitals, Other Health, Presbyopia, ASCRS, Patient, Social media, Near-sightedness, Lens, Cataract, Astigmatism, EVO, STAAR, Surgeon, Publication, Society, Booth, FACS, Multimedia, Behavior, FDA, Reflexive relation, Communications satellite

Furthering the momentum behind its flagship product, EVO ICL, the company is proud to showcase the clinical, practice and innovation advantages through a series of posters, presentations and educational programs.

Key Points: 
  • Furthering the momentum behind its flagship product, EVO ICL, the company is proud to showcase the clinical, practice and innovation advantages through a series of posters, presentations and educational programs.
  • STAAR Surgical can be found at Booth 527 and additional ASCRS event information is available at https://ascrs.org/annual-meeting .
  • View the full release here: https://www.businesswire.com/news/home/20240402599401/en/
    “EVO ICL is the next logical step in refractive innovation.
  • The website offers surgeons access to a wealth of resources, including publications, key clinical outcomes data, and more.

Qlaris Bio’s Novel IOP-Lowering Product, QLS‑111, is Dosed in Phase II Trials

Retrieved on: 
Tuesday, April 2, 2024
Health, Clinical Trials, Research, Science, Optical, Biotechnology, IOP, Kiwi (bird), Ocular hypertension, OAG, Glaucoma, Pressure, EVP, OHT, NTG, Patient, Ageing, Hyperaemia, Humour, Latanoprost, ATP, Safety, Pharmaceutical industry

Qlaris Bio, Inc. (“Qlaris”), a clinical-stage biotechnology company targeting unmet needs in debilitating ophthalmic diseases, today announced the initiation and dosing of two separate U.S.

Key Points: 
  • Qlaris Bio, Inc. (“Qlaris”), a clinical-stage biotechnology company targeting unmet needs in debilitating ophthalmic diseases, today announced the initiation and dosing of two separate U.S.
  • Phase II masked, randomized clinical trials investigating QLS‑111 in patients with ocular hypertension and glaucoma.
  • “The start of these Phase II trials represents a key milestone in our goal of bringing QLS‑111 to glaucoma patients for whom consistent IOP lowering and control has been an unachievable goal,” said Thurein Htoo, Chief Executive Officer.
  • “IOP remains the only modifiable risk factor for the treatment of glaucoma, and additional treatments are needed for patients.

Toku Appoints Former Google Head of Cardiovascular Health as Chief Health Officer

Retrieved on: 
Tuesday, April 2, 2024
Health, Technology, Optical, Health Technology, Artificial Intelligence, Associate, Stanford University, Eye, American Heart, Multimedia, Research, Pharmaceutical industry

Toku is delighted to announce the appointment of Professor Michael V. McConnell, MD, MSEE to the role of Chief Health Officer.

Key Points: 
  • Toku is delighted to announce the appointment of Professor Michael V. McConnell, MD, MSEE to the role of Chief Health Officer.
  • Professor McConnell’s former roles include Director of Advanced Cardiovascular Imaging and Preventive Cardiology at Stanford University and Head of Cardiovascular Health Innovations at Google.
  • He is also a founding member of the American Heart Association’s Health Tech Advisory Group and author of Fight Heart Disease Like Cancer.
  • Mike combines clinical and research expertise, successful business experience, and a passion to have a global impact.

Aurion Biotech to Present Clinical Data at the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

Retrieved on: 
Tuesday, April 2, 2024
Biotechnology, Health, Pharmaceutical, Optical, Clinical Trials, IOTA, ROCK, O.D, Comparison, Cell, Eye, Refractive surgery, Port, ASCRS, BCEC, Patient, Cataract, Senior, Society, Safety, PMDA, Convention center, Annual general meeting, Ophthalmology

Aurion Biotech , whose mission is to restore vision to millions of patients with life-changing regenerative therapies, today announced several presentations during the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting to be held April 5-8, 2024 in Boston, Massachusetts.

Key Points: 
  • Aurion Biotech , whose mission is to restore vision to millions of patients with life-changing regenerative therapies, today announced several presentations during the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting to be held April 5-8, 2024 in Boston, Massachusetts.
  • “We are delighted to share additional insights into these clinical studies, in multiple sessions at the Eyecelerator and ASCRS 2024 meetings,” said Michael Goldstein, M.D., president and chief medical officer, Aurion Biotech.
  • The ABA-1 / CLARA trial is designed to assess the safety, tolerability, and efficacy of AURN001 for the treatment of corneal edema secondary to corneal endothelial dysfunction.
  • The primary endpoint is the percentage of subjects who gain 3 lines of vision at 6 months.

LENZ Therapeutics to Host Investor Call to Discuss Topline Results from the Phase 3 CLARITY Presbyopia Trials

Retrieved on: 
Tuesday, April 2, 2024
Biotechnology, Health, Pharmaceutical, Optical, Clinical Trials, Webcast, Safety, Therapy, Presbyopia

ET to discuss the topline results from its Phase 3 CLARITY study, a group of three multi-center, double-masked, randomized active and vehicle-controlled clinical trials evaluating the efficacy and safety of two investigational formulations of aceclidine, LNZ100 and LNZ101, for the treatment of presbyopia.

Key Points: 
  • ET to discuss the topline results from its Phase 3 CLARITY study, a group of three multi-center, double-masked, randomized active and vehicle-controlled clinical trials evaluating the efficacy and safety of two investigational formulations of aceclidine, LNZ100 and LNZ101, for the treatment of presbyopia.
  • The Company will host a conference call and webcast tomorrow, Wednesday, April 3, 2024, at 8:00 a.m.
  • ET to discuss the topline results.
  • The live webcast and materials from the conference call can be accessed here and on the LENZ Therapeutics website at www.LENZ-tx.com in the Investors & Media section or by calling 877-315-3033 or 215-268-9883.

Eye Physicians of Libertyville Acquires Northern Illinois Eye Clinic

Retrieved on: 
Monday, April 1, 2024
Other Consumer, Women, Men, Family, Other Health, Managed Care, Health, Consumer, Optical, MD, Patient, Multimedia, Acquisition, Cataract, Hospital

Effective March 28, 2024, Eye Physicians of Libertyville doctors will assume care for Northern Illinois Eye Clinic patients.

Key Points: 
  • Effective March 28, 2024, Eye Physicians of Libertyville doctors will assume care for Northern Illinois Eye Clinic patients.
  • View the full release here: https://www.businesswire.com/news/home/20240401980606/en/
    (left) Dr. Nathan Goldberg, Optometrist, Eye Physicians of Libertyville (right) Hercules Logothetis, MD, Owner and Surgeon, Eye Physicians of Libertyville (Photo: Business Wire)
    “Dr.
  • Velotta is a well-respected ophthalmologist in our community, and I wish her the best as she begins her new opportunity,” said Hercules Logothetis, MD, owner and surgeon at Eye Physicians of Libertyville.
  • For more information about Eye Physicians of Libertyville, please visit www.libertyvilleeye.com .

Glaukos To Present Numerous Scientific Abstracts at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting

Retrieved on: 
Monday, April 1, 2024
Research, Surgery, Medical Devices, Health Technology, Health, Pharmaceutical, General Health, Optical, Science, Retina, Glaucoma, Refractive surgery, ASCRS, Corporation, Faculty, Cataract, Society, GKOS, Convention center, Physician

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that it will present multiple scientific abstracts at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, being held April 5-8, 2024 in Boston, MA.

Key Points: 
  • Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that it will present multiple scientific abstracts at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, being held April 5-8, 2024 in Boston, MA.
  • Glaukos will be exhibiting onsite at booth #631.
  • The faculty includes Ike Ahmed, MD (Moderator); Sahar Bedrood, MD; John Berdahl, MD; Manjool Shah, MD; and Blake Williamson, MD.
  • The ASCRS Annual Meeting is among the largest gatherings of anterior segment physicians, medical personnel and industry executives in the ophthalmic industry.

LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Monday, April 1, 2024
Optical, Health, Medical Devices, Employment

LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”) today announced that a majority of the independent members of LENSAR’s board of directors granted three newly-hired non-executive employees stock options to purchase an aggregate of 1,425 shares of the Company’s common stock.

Key Points: 
  • LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”) today announced that a majority of the independent members of LENSAR’s board of directors granted three newly-hired non-executive employees stock options to purchase an aggregate of 1,425 shares of the Company’s common stock.
  • The options were granted as of April 1, 2024, as inducements material to each employee entering into employment with the Company.
  • The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The options are subject to the terms and conditions of LENSAR’s 2024 Employment Inducement Incentive Award Plan and a stock option agreement covering the grant.

Aurion Biotech Announces First Canadian Subject Dosed in Phase 1 / 2 Clinical Trial

Retrieved on: 
Thursday, March 28, 2024
Biotechnology, Health, Pharmaceutical, Optical, Clinical Trials, MD, MBA, Patient, Eye, Safety, Pharmaceutical industry

Aurion Biotech , whose mission is to restore vision to millions of patients with life-changing regenerative therapies, today announced that it has dosed the first Canadian subject in its Phase 1 / 2 clinical trial (ABA-1, CLARA) of AURN001, a cell therapy for the treatment of corneal edema secondary to corneal endothelial dysfunction.

Key Points: 
  • Aurion Biotech , whose mission is to restore vision to millions of patients with life-changing regenerative therapies, today announced that it has dosed the first Canadian subject in its Phase 1 / 2 clinical trial (ABA-1, CLARA) of AURN001, a cell therapy for the treatment of corneal edema secondary to corneal endothelial dysfunction.
  • “We are very pleased to have begun dosing subjects in this trial in Canada,” said Michael Goldstein, MD, MBA, President and Chief Medical Officer of Aurion Biotech.
  • “Treating subjects in both the United States and Canada in our CLARA trial is an important milestone in our clinical development program.
  • The Phase 1 / 2 clinical trial (ABA-1, CLARA) is a prospective, multi-center, randomized, double masked, parallel-arm cell dose-ranging clinical trial in subjects with corneal edema secondary to corneal endothelial dysfunction.

Azura Ophthalmics to Present New Data Supporting the Potential of AZR-MD-001 to be the First Ophthalmic Keratolytic for Ocular Surface Diseases

Retrieved on: 
Thursday, March 28, 2024
Biotechnology, Health, Pharmaceutical, Optical, Clinical Trials, Research, CLD, Refractive surgery, ASCRS, Patient, Telecanthus, ARVO, University, Cataract, Abstract, Eyelid, Detail, Society, University of California, Irritation, Safety, MGD, Pain, Ophthalmic, Pharmaceutical industry

Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a potential new therapeutic class of Ophthalmic Keratolytics for ocular surface diseases, today announced multiple presentations highlighting positive efficacy and safety data from Phase 2 studies of the company’s lead drug candidate, AZR-MD-001, in Meibomian Gland Dysfunction (MGD).

Key Points: 
  • Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a potential new therapeutic class of Ophthalmic Keratolytics for ocular surface diseases, today announced multiple presentations highlighting positive efficacy and safety data from Phase 2 studies of the company’s lead drug candidate, AZR-MD-001, in Meibomian Gland Dysfunction (MGD).
  • This includes new, long-term data at ASCRS of the company’s lead drug candidate, AZR-MD-001, showing improvement in both signs and symptoms in MGD and Contact Lens Discomfort (CLD).
  • “Together, the data set we are presenting at these prestigious conferences show multiple potential patient benefits and mild, transient side effects in a topical medicine, supporting the potential of AZR-MD-001 as an entirely new approach targeting the underlying cause of many ocular surface diseases,” said Marc Gleeson, Chief Executive Officer of Azura.
  • This causes inflammatory ocular surface conditions, ocular surface dryness, pain, irritation, and reduced quality of vision.